Response to trans-retinoic acid in an AMLM3 patient resistant to cis-retinoic acid.
McCarthy
D
D
Samson
D
D
Mir
N
N
Rule
S
S
Nadir
F
F
Taylor
J
J
Costello
C
C
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008130:Lomustine / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D013237:Stereoisomerism; D014212:Tretinoin / Q000627:therapeutic use*
D003561:Cytarabine; D014212:Tretinoin; D005047:Etoposide; D008130:Lomustine; D003630:Daunorubicin